James Flynn Reports a 4% Position in Cancer Genetics

A new filing with the Securities and Exchange Commission has revealed that James E. Flynn, and his hedge fund Deerfield Management now hold a 4.01% stake in Cancer Genetics Inc (NASDAQ:CGIX). The new position in the equity portfolio of Deerfield contains 354,180 shares.

Cancer Genetics

Disclosure: none

Recommended Reading:

Phil Frohlich & Prescott Continue to Buy China Marine Food Group

Hedge Fund Guru Donald Smith Increases Position in Alliance One to 10.26%

This Under-The-Radar Stock Could Save A Buffett Favorite Millions